WO2004085428A1 - Nouveau procede de preparation d'olmesartan medoxomil - Google Patents
Nouveau procede de preparation d'olmesartan medoxomil Download PDFInfo
- Publication number
- WO2004085428A1 WO2004085428A1 PCT/CN2004/000200 CN2004000200W WO2004085428A1 WO 2004085428 A1 WO2004085428 A1 WO 2004085428A1 CN 2004000200 W CN2004000200 W CN 2004000200W WO 2004085428 A1 WO2004085428 A1 WO 2004085428A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- group
- compound
- phenyl
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the invention relates to a method for preparing olmesartan medoxomil. Background technique
- Olmesartan medoxomil is a new blood pressure lowering drug. It is an angiotensin II receptor antagonist and exerts a hypotensive effect by affecting the renin-angiotensin-aldosterone system. Its chemical name is: 4- (1-Hydroxymethylethyl) -2-propyl-1- ⁇ 4- [2- (tetrazol-5-yl) phenyl] phenyl ⁇ methylimidazole-5 -Carboxylic acid (5-methyl-2-oxo-1,3-dioxolene-4-yl) methyl ester; English name: Olmesartan Medoxomil, CAS Accession No .: 144689-63-4; molecular formula : C 29 H 3 . N 6 0 6 , molecular weight: 558.59, appearance: white powder crystal, chemical structure formula is as follows:
- Japanese JP (31) 27098, European Patent EP503785, CN106563A, CN1381453A, Journal of Medical Chemistry, 1996 5 Vol. 39, No: l 323-338 have all reported the preparation method of olmesartan medoxomil.
- the method is based on the connection of an imidazole moiety with a biphenyl moiety, and the reaction results in etherification of the hydroxyl group at the 4-position (1-hydroxy-1-methylethyl) with the biphenyl moiety to cause a by-product, leading to selection It has the disadvantages of poor performance, many by-products, difficult subsequent separation, and low yield.
- the technical problem to be solved by the present invention is to disclose a new method for preparing olmesartan medoxomil, in order to overcome the disadvantages of the existing technology, such as many side reactions, harsh reaction conditions, inconvenient operation, and low yield.
- the method of the present invention includes the following steps:
- the alkali is preferably alkali metal hydroxide, alkali metal carbonate, alkali metal bicarbonate. Including lithium hydroxide, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate;
- the acids include hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid and phosphoric acid;
- the solvent is preferably an alcohol such as methanol or ethanol; an ether such as tetrahydrofuran or dioxane; a sulfoxide such as dimethyl sulfoxide; an amide such as ⁇ , ⁇ -dimethylformamide, ⁇ , N-diethylformamide, N, N-dimethylacetamide; ketones, such as acetone; water; or a mixture of water and one or more of the above organic solvents.
- an alcohol such as methanol or ethanol
- an ether such as tetrahydrofuran or dioxane
- a sulfoxide such as dimethyl sulfoxide
- an amide such as ⁇ , ⁇ -dimethylformamide, ⁇ , N-diethylformamide, N, N-dimethylacetamide
- ketones such as acetone
- water or a mixture of water and one or more of the above organic solvents.
- the reaction temperature can be within a certain width, and the precise temperature is not important to the reaction. Usually -20 ° C ⁇ 120 ° C, preferably 0 ° C ⁇ 100 ° C.
- the reaction time is based on the complete reaction, and is usually 30 minutes to 24 hours.
- RR 2 and R 3 represent a hydrogen atom or a fluorenyl group of 1 to 6 carbon atoms, and RR 2 and R 3 may be the same or different;
- R 4 represents a carboxylic acid, a tetrazol-5-yl group, a cyano group, a protected carboxyl group, a protected tetrazol-5-yl group, a carbamoyl group, or an alkylcarbamoyl group.
- the compound represented by (I) can be prepared by the method reported in the Chinese patent 03115940.0 previously applied by the inventor.
- the preparation method includes the following steps:
- the compound represented by formula (III) undergoes an intramolecular cyclization reaction under the action of a cyclizing agent to obtain a compound represented by formula (IV), and then reacts with a compound represented by formula (V) to obtain the compound represented by (I) compound of.
- the compounds represented by the formula (III) and the formula (V) can be prepared by the method disclosed in the Journal of Medical chemistry, 1996, Vol. 39, No: 1 323-338, or by the commercially available Guang-kou o and
- the cyclizing agent is a general conventional cyclizing agent, including inorganic acids, such as hydrochloric acid, hydrobromic acid, sulfuric acid and phosphoric acid; carbodiimides, such as dicyclohexylcarbodiimide; acids and anhydrides: trifluoroacetic acid, trifluoro Acetic anhydride; and dichlorosulfoxide.
- R 1? R 2 and R 3 represent: a hydrogen atom or an alkyl group of 1 to 6 carbon atoms, and R 3 may be the same or different.
- R P R 2 and R 3 have the same definitions as above;
- X represents a halogen atom,
- R 4 represents a carboxylic acid, a tetrazol-5-yl group, a cyano group, a protected hydroxyl group, a protected tetrazol-5-yl group, Carbamoyl or alkylcarbamoyl.
- solvents mentioned are preferably solvent amides, such as N, N-dimethylformamide, N, N-dimethylacetamide, N, N-diethylformamide; ketones, such as acetone; ethers, Such as tetrahydrofuran or dioxane;
- the reaction temperature can be within a certain width, and the precise temperature is not important for the reaction. Usually 0-120 ° C, preferably 20-80 ° C. Under preferred conditions, the reaction time is usually only 15 minutes to 5 hours.
- the protective group on the tetrazolyl group is then removed under the action of an acid.
- the reaction is usually preferably carried out in the presence of a solvent.
- the reaction solvent has no particular limitation on the nature of the solvent used, as long as there is no side reaction to the reaction or the reagent used.
- the solvent used can dissolve or to some extent the reagents used. Suitable solvents are: water; organic acids, such as acetic acid; ketones, such as acetone or methyl ethyl ketone; ethers, such as tetrahydrofuran, dioxane; or a mixture of any two or more of these solvents. Among them, water, organic acids, alcohols or mixtures thereof are preferred.
- the reaction temperature can be within a certain width, and the precise temperature is not important for the reaction. Usually 0 ° C ⁇ 120 ° C, preferably 0 ° C ⁇ 100 ° C. Under preferred conditions, the reaction time is usually only 30 minutes to 24 hours. It is preferably 1 to 16 hours.
- step (2) is as follows:
- HN is the target product olmesartan medoxomil ( ⁇
- the olmesartan medoxomil prepared by the method disclosed in the present invention has few by-products, high selectivity, mild reaction conditions, convenient operation, and convenient industrial production. detailed description
- the reaction solution was transferred to a separating funnel, and 40 ml of ethyl acetate and 100 ml of water were added. The organic layer was separated, and the aqueous layer was extracted with 20 ml of ethyl acetate. The organic layer was washed once with saturated brine, dried over anhydrous magnesium sulfate, and the solvent was distilled off to obtain 2.47 g of the title compound.
- ⁇ -NMRCDMSO-de ⁇ OOMHz ⁇ 7.7-7.5 (4 ⁇ , multiplet), 7.05 (2 ⁇ , doublet) 6.88 (2 ⁇ , doublet), 5.42 (2 ⁇ , singlet), 5.05 (2 ⁇ , Singlet) 2.60 (2 ⁇ , triplet), 2.07 (3 ⁇ , singlet), 1.59 (2 ⁇ , singlet), 1.48 (6 ⁇ , singlet), 0.87 (3 ⁇ , triplet)
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN03115983.4 | 2003-03-25 | ||
CNB031159834A CN1271068C (zh) | 2003-03-25 | 2003-03-25 | 一种奥美沙坦酯的制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004085428A1 true WO2004085428A1 (fr) | 2004-10-07 |
Family
ID=33035139
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2004/000200 WO2004085428A1 (fr) | 2003-03-25 | 2004-03-12 | Nouveau procede de preparation d'olmesartan medoxomil |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN1271068C (zh) |
WO (1) | WO2004085428A1 (zh) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007017135A2 (en) | 2005-07-29 | 2007-02-15 | Krka | Process for the preparation of olmesartan medoxomil |
WO2007148344A2 (en) * | 2006-06-19 | 2007-12-27 | Matrix Laboratories Limited | Process for the preparation of olmesartan medoxomil |
US7528258B2 (en) | 2004-09-02 | 2009-05-05 | Teva Pharmaceutical Industries Ltd | Preparation of olmesartan medoxomil |
JP2010505926A (ja) * | 2006-10-09 | 2010-02-25 | シプラ・リミテッド | トリチルオルメサルタンメドキソミルおよびオルメサルタンメドキソミルの製造方法 |
US7834042B2 (en) * | 2006-11-17 | 2010-11-16 | Merck Sharp & Dohme Corp. | Angiotensin II receptor antagonists |
JP2012508695A (ja) * | 2008-11-17 | 2012-04-12 | 浙江海正薬業股▲ふん▼有限公司 | 4−(1−ヒドロキシ−1−メチルエチル)−2−プロピルイミダゾール−5−カルボン酸エステルの製造方法 |
WO2014034868A1 (ja) | 2012-08-31 | 2014-03-06 | 株式会社エーピーアイ コーポレーション | ビアリール化合物の製造方法 |
WO2014051008A1 (ja) | 2012-09-26 | 2014-04-03 | 株式会社エーピーアイ コーポレーション | テトラゾール化合物の脱保護方法 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008050714A1 (fr) * | 2006-10-25 | 2008-05-02 | Daiichi Sankyo Company, Limited | Matériel de conditionnement |
CN103044407A (zh) * | 2012-12-20 | 2013-04-17 | 安徽悦康凯悦制药有限公司 | 奥美沙坦酯的制备方法 |
CN105418593A (zh) * | 2015-11-25 | 2016-03-23 | 蚌埠丰原涂山制药有限公司 | 一种奥美沙坦酯关键中间体及奥美沙坦酯的制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0753489A (ja) * | 1993-06-11 | 1995-02-28 | Sankyo Co Ltd | ビフェニルカルボキサミド誘導体の製造法 |
US5744612A (en) * | 1996-03-21 | 1998-04-28 | Toyo Kasei Kogyo Company Limited | Process for preparation of 5- substituted tetrazoles |
CN1381453A (zh) * | 2002-05-17 | 2002-11-27 | 浙江省医学科学院 | 一种新的奥美沙坦的制备方法 |
CN1467209A (zh) * | 2003-03-21 | 2004-01-14 | 上海医药工业研究院 | 4,6-二氢呋喃并[3,4-d]咪唑-6-酮衍生物及其盐和制备方法 |
-
2003
- 2003-03-25 CN CNB031159834A patent/CN1271068C/zh not_active Expired - Fee Related
-
2004
- 2004-03-12 WO PCT/CN2004/000200 patent/WO2004085428A1/zh active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0753489A (ja) * | 1993-06-11 | 1995-02-28 | Sankyo Co Ltd | ビフェニルカルボキサミド誘導体の製造法 |
US5744612A (en) * | 1996-03-21 | 1998-04-28 | Toyo Kasei Kogyo Company Limited | Process for preparation of 5- substituted tetrazoles |
CN1381453A (zh) * | 2002-05-17 | 2002-11-27 | 浙江省医学科学院 | 一种新的奥美沙坦的制备方法 |
CN1467209A (zh) * | 2003-03-21 | 2004-01-14 | 上海医药工业研究院 | 4,6-二氢呋喃并[3,4-d]咪唑-6-酮衍生物及其盐和制备方法 |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7528258B2 (en) | 2004-09-02 | 2009-05-05 | Teva Pharmaceutical Industries Ltd | Preparation of olmesartan medoxomil |
WO2007017135A2 (en) | 2005-07-29 | 2007-02-15 | Krka | Process for the preparation of olmesartan medoxomil |
WO2007148344A2 (en) * | 2006-06-19 | 2007-12-27 | Matrix Laboratories Limited | Process for the preparation of olmesartan medoxomil |
WO2007148344A3 (en) * | 2006-06-19 | 2008-04-24 | Matrix Lab Ltd | Process for the preparation of olmesartan medoxomil |
JP2010505926A (ja) * | 2006-10-09 | 2010-02-25 | シプラ・リミテッド | トリチルオルメサルタンメドキソミルおよびオルメサルタンメドキソミルの製造方法 |
US8076492B2 (en) | 2006-10-09 | 2011-12-13 | Cipla Limited | Process for preparing trityl olmesartan medoxomil and olmesartan medoxomil |
US7834042B2 (en) * | 2006-11-17 | 2010-11-16 | Merck Sharp & Dohme Corp. | Angiotensin II receptor antagonists |
JP2012508695A (ja) * | 2008-11-17 | 2012-04-12 | 浙江海正薬業股▲ふん▼有限公司 | 4−(1−ヒドロキシ−1−メチルエチル)−2−プロピルイミダゾール−5−カルボン酸エステルの製造方法 |
WO2014034868A1 (ja) | 2012-08-31 | 2014-03-06 | 株式会社エーピーアイ コーポレーション | ビアリール化合物の製造方法 |
US9624181B2 (en) | 2012-08-31 | 2017-04-18 | Api Corporation | Method for producing biaryl compound |
WO2014051008A1 (ja) | 2012-09-26 | 2014-04-03 | 株式会社エーピーアイ コーポレーション | テトラゾール化合物の脱保護方法 |
US9527821B2 (en) | 2012-09-26 | 2016-12-27 | Api Corporation | Deprotection method for tetrazole compound |
Also Published As
Publication number | Publication date |
---|---|
CN1532195A (zh) | 2004-09-29 |
CN1271068C (zh) | 2006-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2019825B9 (en) | Inhibitors of human immunodeficiency virus replication | |
JP5269798B2 (ja) | トリチルオルメサルタンメドキソミルおよびオルメサルタンメドキソミルの製造方法 | |
TW304941B (zh) | ||
WO1999016766A1 (fr) | Derives de benzodioxole | |
WO2004085428A1 (fr) | Nouveau procede de preparation d'olmesartan medoxomil | |
DK163431B (da) | Analogifremgangsmaade til fremstilling af 4-phenyl-1,3-dioxan-cis-5-ylalken- eller alkansyrederivater | |
WO1997044306A1 (fr) | Derives de chalcone et medicaments les contenant | |
EP0540400B1 (fr) | Dérivés de quinoléine, utile comme angiotensine II antagonistes | |
WO2016180033A1 (zh) | 一种前列环素受体激动剂的制备方法 | |
JP2010505836A (ja) | ヒンバシンの修飾された三環単位に基づいたトロンビン受容体アンタゴニスト | |
CN1034171C (zh) | 制备新的取代的4-嘧啶酮衍生物的方法 | |
US20130190506A1 (en) | Process for olmesartan medoxomil | |
HUT58311A (en) | Process for producing antiviral (thio)morpholinyl- and piperazinyl-alkyl-phenol-ether derivatives and pharmaceutical compositions containing them | |
MX2007007303A (es) | Proceso para preparar olmesartan medoxomil a ph superior a 2,5. | |
KR101459301B1 (ko) | 몬테루카스트 나트륨 중간체의 합성 방법 | |
JPS5859980A (ja) | カルボスチリル誘導体 | |
JP2873599B2 (ja) | 新規ベンゾフラン誘導体、尿酸排泄剤及びその製法 | |
JPH06100448A (ja) | シクロアルカン誘導体、その製造方法およびそれを含有するロイコトリエンが介在する疾患または症状に使用するための調剤学的組成物 | |
WO2014111903A2 (en) | A process for the preparation of 6-fluoro-3,4-dihydro-2h-chromene- 2-carbaldehyde | |
TW200418850A (en) | Acyl derivatives of 5-(2-(4-(1,2 benzisothiazole-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one having neuroleptic activity | |
WO2004083213A1 (fr) | Derives de 4,6-dihydrofuro[3,4-d]imidazole-6-one, sels de ceux-ci ainsi que procede de preparation associe | |
JP2722673B2 (ja) | 光学活性なアシルビフェニル誘導体の製造法 | |
JP2002501064A (ja) | 複素芳香環縮合シクロペンテノピリジン誘導体 | |
JP3533567B2 (ja) | 置換アニリンから置換キノリンを製造する新規合成法 | |
CN101328167A (zh) | 一种洛沙坦的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
122 | Ep: pct application non-entry in european phase |